Today: 3 July 2026
WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus
9 January 2026
1 min read

WD-40 stock slides 6% after Q1 profit falls; guidance held and Asia rebound in focus

NEW YORK, January 9, 2026, 14:00 ET — Regular session

  • Shares down about 6% as investors react to WD-40’s first-quarter profit drop and higher overhead
  • Company reaffirmed full-year targets, pointing to order timing in distributor markets
  • Traders are watching for more detail at WD-40’s Jan. 13 ICR Conference appearance

WD-40 Company shares fell 5.6% to $192.13 on Friday afternoon, after the lubricant maker posted a drop in first-quarter profit and higher expenses. The stock was down as much as nearly 14% earlier in the session.

The move matters because WD-40 tends to trade like a steady compounder. When profit slips, the market usually asks if it’s just timing — or something that sticks.

Management put the soft patch on distributor markets, where the company sells through third-party partners, and said direct markets kept growing. Investors are now looking for proof in the March quarter, not just talk.

For the quarter ended Nov. 30, net sales rose 1% to $154.4 million while diluted EPS fell to $1.28 from $1.39 a year earlier. Gross margin — what’s left after product costs — climbed to 56.2%, up 140 basis points (1.4 percentage points), but operating income slid 7% to $23.3 million as selling, general and administrative expenses rose 10% to $55.3 million. Maintenance product sales grew 2%, with direct markets that account for about 83% of global sales up 8%, while Asia distributor market sales fell 31%; WD-40 Specialist rose 18% and e-commerce sales were up 22%.

CEO Steve Brass said the second quarter was “off to an excellent start” and he expects a rebound later in the year. CFO Sara Hyzer reaffirmed fiscal 2026 guidance, including net sales of $630 million to $655 million, gross margin of 55.5% to 56.5%, operating income of $103 million to $110 million, and diluted EPS of $5.75 to $6.15, and said management expects to land toward the mid-to-high end of those ranges. WD-40 said it repurchased 39,500 shares in the quarter and had $21.8 million left under its buyback plan, while a $1.02 quarterly dividend is due Jan. 30 to holders of record Jan. 16. Q4 Investments

A quarterly report filed with the U.S. Securities and Exchange Commission on Thursday covered the three months ended Nov. 30, 2025.

The selloff pushed the stock down to about $175 at the session low, putting it at the bottom of its 52-week range of $175.38 to $253.48. It has since regained some ground but remains below $200, a level traders tend to keep on the screen.

But the rebound case depends on distributors restocking on schedule and demand holding up in Asia, where WD-40 saw the sharpest drop. If orders stay lumpy or costs keep running hot, the margin gains may not be enough to protect earnings.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Medicare GLP-1 Bridge Boosts Access, Turns Novo Nordisk (NVO), Lilly (LLY) Obesity Drug Fight to Outcomes
    July 3, 2026, 11:12 AM EDT. Novo Nordisk's NVO Medicare GLP-1 Bridge program started July 1, letting eligible Medicare patients get Wegovy for $50 per month through 2027. That move expands access and helps Novo Nordisk's oral obesity play, which now has more than three million U.S. prescriptions. But Eli Lilly's LLY drugs Zepbound and Foundayo get the same reimbursement, so there's no price edge. Now the competition swings to clinical data and practical differences. Zepbound delivers more weight loss than the Wegovy shot. Foundayo is simpler to dose, but comes with more side effects than Wegovy pills. Novo Nordisk can't lean on pricing and must focus on product results if it wants to keep leading in obesity drugs.
Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14
Previous Story

Kohl’s stock slides 5% as tariff ruling delay hits retailers; KSS traders eye Jan. 14

Constellation Energy (CEG) stock jumps after TD Cowen Buy call; Calpine deal back in focus
Next Story

Constellation Energy (CEG) stock jumps after TD Cowen Buy call; Calpine deal back in focus

Go toTop